An algorithm-based approach to first-episode schizophrenia: Response rates over 3 prospective antipsychotic trials with a retrospective data analysis

Journal of Clinical Psychiatry

Volumn 72, Issue 11, 2011, Pages 1439-1444

  Agid, Ofer ^a,b   Arenovich, Tamara ^b   Sajeev, Gautam ^b   Zipursky, Robert B ^c   Kapur, Shitij ^d   Foussias, George ^a,b   Remington, Gary ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ADULT; ALGORITHM; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CANADA; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FIRST EPISODE SCHIZOPHRENIA; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NATURALISTIC INQUIRY; PRIORITY JOURNAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

EID: 79960320959     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05785yel     Document Type: Article

References (35)

1. National Institute for Clinical Excellence (NICE). Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. NICE Clinical Guideline 82, March 2009. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=nicecg82&part=appendices. app1
2. American Psychiatric Association (APA). Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry. 1997;154(suppl 4):1-63.
3. American Psychiatric Association (APA). Practice Guideline for the Treatment of Patients With Schizophrenia. 2nd ed. Am J Psychiatry. 2004;161(suppl 2):1-56.
4. Kane JM, Leucht S, Carpenter D, et al. Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders: introduction: methods, commentary, and summary. J Clin Psychiatry. 2003;64(suppl 12):5-19. PubMed
5. Lehman AF, Steinwachs DM, and the Co-Investigators of the PORT Project. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull. 1998;24(1):1-10. PubMed (Pubitemid 28128486)
6. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull. 2004;30(2):193-217. PubMed (Pubitemid 38828528)
7. Miller AL, Chiles JA, Chiles JK, et al. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry. 1999;60(10):649-657. PubMed (Pubitemid 29503644)
8. Moore TA, Buchanan RW, Buckley PF, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007;68(11):1751-1762. doi:10.408/JCP.v68n15 PubMed (Pubitemid 350247505)
9. Canadian Psychiatric Association. Clinical practice guidelines: treatment of schizophrenia. Can J Psychiatry. 2005;50(suppl 1):7S-57S. PubMed
10. Essock SM, Covell NH, Davis SM, et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry. 2006;163(12):2090-2095. doi:10.176/api.ajp.163.12.2090 PubMed (Pubitemid 46114228)
11. Rosenheck RA, Davis S, Covell N, et al. Does switching to a new antipsychotic improve outcomes? data from the CATIE Trial. Schizophr Res. 2009;107(1):22-29. doi:10.1016/j.schres.208.09.031 PubMed
12. Davis JM, Marder SR, Tamminga CA. Switch or stay? Am J Psychiatry. 2006;163(12):2032-2033. doi:10.176/api.ajp.163.12.2032 PubMed (Pubitemid 46114216)
13. McEvoy JP, Lieberman JA, Stroup TS, et al. CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600-610. doi:10.176/api.ajp.163.4.60 PubMed (Pubitemid 44464569)
14. Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology. 2003;28(5):995-1003. PubMed
15. Woerner MG, Robinson DG, Alvir JM, et al. Clozapine as a first treatment for schizophrenia. Am J Psychiatry. 2003;160(8):1514-1516. doi:10.176/api.ajp. 160.8.1514 PubMed (Pubitemid 41070929)
16. Agid O, Remington G, Kapur S, et al. Early use of clozapine for poorly responding first-episode psychosis. J Clin Psychopharmacol. 2007;27(4):369-373. doi:10.1097/jcp.0b013e3180d0a6d4 PubMed (Pubitemid 47075508)
17. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology: US Dept Health, Education, & Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:218-222.
18. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10(3):799-812. doi:10.246/PR0.10.3.79-812
19. Zhang J, Yu KF. What's the relative risk? a method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280(19):1690-1691. doi:10.101/jama.280.19.1690 PubMed (Pubitemid 28532993)
20. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999;156(4):544-549. PubMed (Pubitemid 29162974)
21. Szymanski SR, Cannon TD, Gallacher F, et al. Course of treatment response in first-episode and chronic schizophrenia. Am J Psychiatry. 1996;153(4):519-525. PubMed (Pubitemid 26113316)
22. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789-796. PubMed
23. Tandon R, Belmaker RH, Gattaz WF, et al. Section of Pharmacopsychiatry, World Psychiatric Association. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr Res. 2008;100(1-3):20-38. doi:10.1016/j.schres.207.1.03 PubMed
24. Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry. 2003;64(1):30-34. doi:10.408/JCP.v64n0107 PubMed (Pubitemid 36182226)
25. Tuunainen A, Wahlbeck K, Gilbody SM. Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database Syst Rev. 2000;(2):CD000966. PubMed
26. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res. 1999;35(1):51-68. doi:10.1016/S0920-964(98)0105-4 PubMed (Pubitemid 29023554)
27. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of secondgeneration antipsychotics. Arch Gen Psychiatry. 2003;60(6):553-564. doi:10.101/archpsyc.60.6.53 PubMed
28. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223. doi:10.1056/NEJMoa05168 PubMed (Pubitemid 41345943)
29. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31-41. doi:10.1016/S0140-6736(08)61764-X PubMed
30. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164(7):1050-1060. doi:10.176/api.ajp.164.7.1050 PubMed (Pubitemid 47121394)
31. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. (published correction appears in N Engl J Med. 2005;353(12):1209-1223. doi:10.1056/ NEJMoa05168 PubMed
32. Robinson DG, Woerner MG, Napolitano B, et al. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry. 2006;163(12):2096-2102. doi:10.176/api.ajp. 163.12.2096 PubMed (Pubitemid 46114229)
33. Depp C, Lebowitz BD. Clinical trials: bridging the gap between efficacy and effectiveness. Int Rev Psychiatry. 2007;19(5):531-539. doi:10.1080/ 0954026070156320 PubMed (Pubitemid 47493737)
34. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63(10):1079-1087. doi:10.101/archpsyc.63.10.1079 PubMed (Pubitemid 44498387)
35. Kahn RS, Fleischhacker WW, Boter H, et al.; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-1097. doi:10.1016/S0140-6736(08)60486-9 PubMed (Pubitemid 351418005)